Cytokinetics/$CYTK
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Cytokinetics
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
- Ticker
- $CYTK
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 673
- Headquarters
- South San Francisco, United States
- Website
- www.cytokinetics.com
Cytokinetics Metrics
BasicAdvanced
$7.5B
-
-$6.02
0.47
-
Price and volume
Market cap
$7.5B
Beta
0.47
52-week high
$88.31
52-week low
$53.55
Average daily volume
2.1M
Financial strength
Current ratio
3.359
Quick ratio
3.197
Long term debt to equity
-3.777
Total debt to equity
-4.484
Interest coverage (TTM)
-5.17%
Profitability
EBITDA (TTM)
-694.49
Gross margin (TTM)
-259.58%
Net profit margin (TTM)
-686.63%
Operating margin (TTM)
-625.15%
Revenue per employee (TTM)
$170,000
Management effectiveness
Return on assets (TTM)
-27.15%
Return on equity (TTM)
184.71%
Valuation
Price to revenue (TTM)
61.258
Price to book
-23.24
Price to tangible book (TTM)
-23.24
Growth
Revenue change (TTM)
29.90%
Earnings per share change (TTM)
-4.75%
3-year revenue growth (CAGR)
143.83%
10-year revenue growth (CAGR)
3.16%
3-year earnings per share growth (CAGR)
2.92%
10-year earnings per share growth (CAGR)
120.68%
What the Analysts think about Cytokinetics
Analyst ratings (Buy, Hold, Sell) for Cytokinetics stock.
Analyst projections of the future price of Cytokinetics stock.
Bulls say / Bears say
MYQORZO’s US launch is gaining pace: third-quarter product revenue rose 76% from the prior quarter to $44.5 million, with more than 2,800 patients dispensed and nearly 1,100 prescribers. That is early evidence of growing demand for the company’s first commercial product. (Cytokinetics)
Aficamten met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive HCM, improving patient-reported health and exercise capacity versus placebo. If regulators approve the expanded use, it could give the company access to patients with a form of HCM that currently has no approved treatment for its underlying cause. (Cytokinetics)
The company is widening MYQORZO’s reach beyond the US: it has approvals in Canada and the UK, with NICE recommending its use in England and Wales, and it has begun selling in Germany. Further country launches could broaden the commercial opportunity, although reimbursement and uptake will take time. (Cytokinetics)
Sales remain small beside the cost base: third-quarter revenue was $47.6 million against a $190.1 million net loss, while the company expects $860–890 million of combined R&D and sales and administrative expenses for 2026. Continued cash outflows may eventually require more financing or dilute shareholders if product growth does not catch up. (Cytokinetics)
Aficamten’s non-obstructive HCM results include a safety concern: reduced heart pumping capacity (LVEF below 50%) occurred in 10.5% of treated patients versus 0.8% on placebo, and serious heart-failure events were more frequent. The trial also did not show a significant benefit on time to a first cardiovascular event, which limits evidence of benefit on harder outcomes. (Cytokinetics, BioPharma Dive)
MYQORZO’s international growth may be slower than approvals suggest: management said meaningful revenue from large European markets such as Italy, Spain and France may not arrive until 2028–29 because of reimbursement negotiations. That delays the payoff from the company’s overseas expansion. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 5 Nov 2026.
Cytokinetics Financial Performance
Revenues and expenses
Cytokinetics Earnings Performance
Company profitability
Upcoming events
No upcoming events
Cytokinetics News
AllArticlesVideos
Funds containing Cytokinetics
AllUSDEURGBP
Fund name | Fund size | $CYTK weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.51% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.51% |
iShares Ageing Population$AGED | $953M | 0.39% |
iShares Ageing Population£AGES | $953M | 0.39% |
iShares Ageing Population€AGED | $903M | 0.39% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.